Nexthera Capital, a hedge fund manager focused on global therapeutics, has appointed Rael Mazansky as director of research.
Working with Nexthera’s co-founder and CIO Ori Hershkovitz (pictured), Mazansky will help drive Nexthera’s investment strategy of seeking high risk-adjusted returns from the healthcare and therapeutics sectors.
“We are excited to hire an individual with a long and impressive history in healthcare investing. Rael will strengthen our team as we continue to develop the best human capital to produce innovative research and guidance for the portfolio,” says Daniel Malek, co-founder and CEO. “Rael’s experience and perspective will help Nexthera attempt to capitalise on dynamic opportunities in this often misunderstood and complex area.”
Mazansky joins Nexthera after being a healthcare portfolio manager at Surveyor Capital (Citadel), and previously holding senior biotech analyst roles at Perceptive Advisors and Ridgeback Capital.
